Steadybase.

Zura Bio Ltd.

Website LinkedIn Latest 10-K
  • ZURA · Nasdaq
  • Biological Products, (No Diagnostic Substances)
  • La Jolla, CA
  • 40 employees
  • CIK 0001855644

Updated from SEC filings through

Top things to know

Employees40As of December 31, 2025
Next earningsFebruary 11, 2027Estimated from past filings
Latest 8-KOther eventsFiled November 9, 2026

Executives

Zura Bio Ltd is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in La Jolla, CA. It trades as ZURA on Nasdaq. It reported about 40 employees.

Five-year financials

MetricFY2025FY2024FY2023FY2022
Revenue Not on file Not on file Not on file Not on file
Operating income -$75.2M
10-K, 2026-03-19
-$55.2M
10-K, 2026-03-19
-$62.6M
10-K, 2025-03-25
-$2.7M
10-K, 2023-03-28
SG&A $33.2M
10-K, 2026-03-19
$30.8M
10-K, 2026-03-19
$18.6M
10-K, 2025-03-25
$2.3M
10-K, 2023-03-28
Net income -$68.7M
10-K, 2026-03-19
-$52.4M
10-K, 2026-03-19
-$60.4M
10-K, 2025-03-25
-$25.7M
10-K, 2024-03-28

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Sandeep Chidambar Kulkarni Chief Executive Officer Form 4, April 2, 2026
Eric J. Hyllengren Chief Financial Officer Form 4, April 2, 2026
Kim Davis Chief Operating Officer, Chief Legal Officer and Corporate Secretary 8-K, May 22, 2026
Kiran Nistala Named in proxy
bio: Chief Medical Officer and Head of Development
DEF 14A, April 30, 2026
Gary Whale Chief Technology Officer Form 4, April 2, 2026
Marlyn Teresa Mathew VP, Principal Acctg. Officer Form 3, June 22, 2026
Asim Mohammed BAFFX17 Parties 10-K, March 19, 2026
Baljit Lehal Stone Peach Parties 10-K, March 19, 2026
Kanwarjeet “Shawn” Tucker Stone Peach Parties 10-K, March 19, 2026
Lahmber Singh BAFFX17 Parties 10-K, March 19, 2026
Amit D. Munshi Board member (per proxy)
bio: Chairman of our Board
DEF 14A, April 30, 2026
Dan Becker, M.D., Ph.D. Board member (per proxy)
bio: director
DEF 14A, April 30, 2026
Mark Eisner, M.D., M.P.H. Board member (per proxy)
bio: director
DEF 14A, April 30, 2026

What Zura Bio Ltd does

We are a clinical-stage biotechnology company developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with significant unmet medical need. These diseases are often chronic, biologically complex and difficult to treat, and many patients do not achieve durable disease control with currently available therapies.

Item 1. Business, 10-K for the year ending December 31, 2025

Shares and governance

Shares outstanding 96.3 million (as of October 27, 2026) 10-Q, October 27, 2026
Public float $59.0M (as of June 30, 2025) 10-K, March 19, 2026
Reportable segments 1 (period ending September 30, 2026) 10-Q, October 27, 2026
Latest proxy statement Meeting June 17, 2026 (filed April 30, 2026) DEF 14A, April 30, 2026
Auditor WithumSmith+Brown, PC (East Brunswick, New Jersey) Latest 10-K

Recent 8-K events

  • 8-K filed 2026-11-09
    • Item 8.01 Other events
  • 8-K filed 2026-10-27
    • Item 2.02 Results of operations and financial condition (earnings release)
    • Item 7.01 Regulation FD disclosure
  • 8-K filed 2026-08-17
    • Item 7.01 Regulation FD disclosure
  • 8-K filed 2026-08-11
    • Item 2.02 Results of operations and financial condition (earnings release)
    • Item 7.01 Regulation FD disclosure
  • 8-K filed 2026-07-01
    • Item 7.01 Regulation FD disclosure
  • 8-K filed 2026-06-18
    • Item 5.02 Departure or appointment of directors or officers; compensation
    • Item 5.07 Submission of matters to a vote of security holders
  • 8-K filed 2026-05-22
    • Item 5.02 Departure or appointment of directors or officers; compensation
  • 8-K filed 2026-05-07
    • Item 2.02 Results of operations and financial condition (earnings release)
    • Item 7.01 Regulation FD disclosure
  • 8-K filed 2026-04-23
    • Item 5.02 Departure or appointment of directors or officers; compensation
  • 8-K filed 2026-03-19
    • Item 2.02 Results of operations and financial condition (earnings release)
    • Item 7.01 Regulation FD disclosure

Frequently asked questions about Zura Bio Ltd

What does Zura Bio Ltd do?
In its own words, from Item 1 of its 10-K: "We are a clinical-stage biotechnology company developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with significant unmet medical need. These diseases are often chronic, biologically complex and difficult to treat, and many patients do not achieve durable disease control with currently available therapies."
How many employees does Zura Bio Ltd have?
About 40 as of December 31, 2025, as stated in its annual report.
Who is the CFO of Zura Bio Ltd?
Eric J. Hyllengren, Chief Financial Officer, as named in a 4 filed April 2, 2026.
Where is Zura Bio Ltd headquartered?
La Jolla, CA.
What is Zura Bio Ltd's stock ticker?
ZURA on Nasdaq.
What industry is Zura Bio Ltd in?
Biological Products, (No Diagnostic Substances), SIC code 2836.
What is Zura Bio Ltd's website?
zurabio.com.
When does Zura Bio Ltd report earnings next?
February 11, 2027. This is an estimate from past filing dates, not a confirmed date.
Is Zura Bio Ltd a public company?
Yes. Zura Bio Ltd files with the SEC under CIK 0001855644 and trades as ZURA.
Who audits Zura Bio Ltd?
WithumSmith+Brown, PC, East Brunswick, New Jersey, as named in its latest annual report (10-K).
How many shares of Zura Bio Ltd are outstanding?
96.3 million shares as of October 27, 2026, from its 10-Q filed October 27, 2026.
What is Zura Bio Ltd's public float?
$59.0M as of June 30, 2025, as reported on the cover of its 10-K filed March 19, 2026.
How many business segments does Zura Bio Ltd report?
1 reportable segment for the period ending September 30, 2026, from its 10-Q filed October 27, 2026.
When is Zura Bio Ltd's annual shareholder meeting?
June 17, 2026, per its proxy statement (DEF 14A) filed April 30, 2026.